Castle Biosciences Inc

NASDAQ:CSTL

65.48

-2.69 (-3.95%)

Market Cap (Intraday)	1.32B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$16.66 Million
Adjusted EPS	-$0.24

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Castle Biosciences, Inc. Stock, NASDAQ:CSTL

820 South Friendswood Drive, Suite 201, Friendswood, Texas 77546

United States of America

Phone: +1.866.788.9007

Number of Employees: 133

http://www.castlebiosciences.com

Description

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.